Peer-reviewed veterinary case report
Retinoid receptor patterns in skin lymphoma tumors of 30 dogs
By de Mello Souza, C H et al.·Published in Journal of veterinary internal medicine·2010·College of Veterinary Medicine, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Immunohistochemical detection of retinoid receptors in tumors from 30 dogs diagnosed with cutaneous lymphoma.
- Species:
- dog
Plain-English summary
A study looked at biopsy samples from 30 dogs diagnosed with skin cancer called cutaneous lymphoma. The researchers found that most of these dogs had a specific type of receptor (RARβ) present in their tumors, which could be important for treatment. Since these receptors can be targeted by certain medications, this finding suggests that using drugs that bind to these receptors might help improve treatment options for dogs with this type of cancer.
People also search for: dog skin cancer treatment · cutaneous lymphoma in dogs · retinoid drugs for dogs
Abstract
BACKGROUND: Retinoids exert their effects by binding to retinoid receptors. Two types of retinoid receptors have been described: retinoic acid receptor (RAR) and retinoid X receptor (RXR), and their subtypes α, β, and γ. The expression of subtypes varies depending on the disease process. This study intended to detect the pattern of retinoid receptor expression in cutaneous lymphomas in dogs. HYPOTHESIS: Cutaneous lymphomas in dogs have variable expression of retinoid and retinoid X receptors. ANIMALS: Biopsy specimens from 30 dogs with cutaneous lymphoma. METHODS: Tissues of dogs with cutaneous lymphoma were evaluated by immunohistochemistry for expression of retinoid receptors. The tissues were tested for the presence of 3 RAR and RXR subtypes (α, β, and γ). Lymphoma immunophenotype was determined by the use of the immunohistochemical markers CD79a (B-cell) and CD3 (T-cell) in all cases. RESULTS: Twenty-nine of 30 dogs were CD3 positive. The retinoid receptors expressed with the greatest frequency were RARβ (87% of cases), and RXRα and RXRγ (77% of cases). The expression of RARγ was not observed. CONCLUSIONS AND CLINICAL RELEVANCE: Retinoid and rexinoid receptor binding drugs may have an impact on the treatment of dogs with cutaneous lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/20707846/